Company Overview and News
VANCOUVER, British Columbia, March 28, 2018 (GLOBE NEWSWIRE) -- Metallis Resources Inc. (TSX-V:MTS) (“Metallis” or the “Company”) announces that Geotech Ltd. has completed the 2018 airborne versatile time-domain electromagnetic survey (“VTEM Survey”) over its Thunder North, Thunder South and King areas within its 100% owned Kirkham Property. Click here for 2018 VTEM area block map.
TORONTO, March 22, 2018 (GLOBE NEWSWIRE) -- Nautilus Minerals Inc. (TSX:NUS) (OTC:NUSMF) (Nasdaq Intl Designation) (the "Company" or "Nautilus") announces that Mr. Jay Layman has been appointed to the role of independent non-executive Director.
TORONTO, March 21, 2018 (GLOBE NEWSWIRE) -- Seabridge Gold (TSX:SEA) (NYSE:SA) announced that its Form 40-F has been filed with the SEC on EDGAR (www.sec.gov/). The Company’s Shareholders may, upon request, receive a hard copy of the Company's complete 2017 audited financial statements free of charge. To review these documents on the Company’s website, please see http://www.seabridgegold.net/sharefinrep.
TORONTO, March 20, 2018 (GLOBE NEWSWIRE) -- Seabridge Gold (TSX:SEA) (NYSE:SA) announced today that it has filed its Audited Consolidated Financial Statements and its Management's Discussion and Analysis for the year ended December 31, 2017 on SEDAR (www.sedar.com). To review these documents on the Company website, please see http://www.seabridgegold.net/sharefinrep.php.
As of this writing on January 21, I am revisiting the sector and what I see as a train wreck and bear market. The two mania stocks, Riot Blockchain (RIOT) and LongFin Corp (LFIN), have dropped between 50% and 75%. Global Blockchain (OTCQB:BKDCF) dropped to C$1.40 and is currently in the C$1.60s.
Novo Resources (OTCQX:NSRPF) is a Vancouver-based junior mining exploration company that is in the early stages of exploring its Karratha gold project in Australia. It also has another gold project, Beatons Creek, in Australia and a property in Nevada. Novo had an extraordinary run in price starting in early July, when it ran from 63 cents (US$) to US$7 by the early October. At its peak valuation, its market cap was $1.
This copy is for your personal non-commercial use only. To order presentation-ready copies of Toronto Star content for distribution to colleagues, clients or customers, or inquire about permissions/licensing, please go to: www.TorontoStarReprints.com
TORONTO -- Seabridge Gold Inc. (TSX:SEA) says a federal agency has dismissed a complaint by Alaskan conservationists against the company's massive KSM mining project in northern British Columbia.
Paramount Gold (NYSEMKT:PZG) owns a 100% interest in the Grassy Mountain Gold Project in eastern Oregon and a 100% interest in the Sleeper Gold Project in northern Nevada. Over the past few months some subscribers have asked my opinion on the Paramount Gold. I owned the old Paramount Gold & Silver several years before Coeur Mining acquired it in December 2014 for $146 million in stock. As part of that deal, Paramount's non-Mexican assets were spun-off to management.
My good friend Pierre Lassonde, co-founder and chairman of Franco-Nevada Corp. (NYSE:FNV), said he doesn’t know how we’ll replace the massive gold deposits of the past 130 years or so. Speaking with the German financial newspaper Finanz und Wirtschaft this month, Pierre noted we’re seeing a significant slowdown in the number of large deposits being discovered. Legendary goldfields, such as South Africa’s Witwatersrand Basin, Nevada’s Carlin Trend and Australia’s Super Pit - all nearing the end of their lifecycles - could very well be a thing of the past.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...